Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25472073 | 0.98 | KDM4E (0.43) | KDM4EFPR3FPR2HRH3HTR2A | |
| SCHEMBL25472080 | 0.96 | LTA4H (0.46) | KDM4EFPR3FPR2HRH3HTR2A | |
| SCHEMBL25470500 | 0.93 | KDR (0.44) | HRH3HTR2AHTR1ADRD2NPC1 | |
| SCHEMBL25472000 | 0.92 | SIGMAR1 (0.41) | KDM4EFPR3FPR2HTR2AL3MBTL1 | |
| SCHEMBL25472017 | 0.91 | FPR3 (0.39) | KDM4EFPR3FPR2HRH3HTR2A | |
| SCHEMBL25472032 | 0.90 | HTR2A (0.38) | KDM4EFPR3FPR2HRH3HTR2A | |
| SCHEMBL25472046 | 0.90 | HTR4 (0.40) | KDM4EFPR3FPR2HTR2AL3MBTL1 | |
| SCHEMBL25472002 | 0.90 | PPARG (0.39) | KDM4EFPR3FPR2HRH3HTR2A | |
| SCHEMBL26437789 | 0.90 | KDM4E (0.37) | KDM4EFPR3FPR2HRH3HTR2A | |
| SCHEMBL25472050 | 0.89 | L3MBTL1 (0.38) | KDM4EHRH3HTR2AHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230147603-A1 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | PROSETTA BIOSCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | KDM4E 4045/4885FPR3 845/4885FPR2 1174/4885 |
| US-20230147603-A1 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | MAVS, SARS1, ZC3HAV1 | KDM4E 4045/4885FPR3 845/4885FPR2 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.